Deals Of The Week: Mylan/Biocon, Merck/Lycera, Lilly/Qiagen
A pending regulatory decision in the U.S. and Europe for oncology drug RA 223 and improving sales of AMD drug Eylea, both brought in through partnership activity, may bring some calm to the recently stormy seas traveled by Bayer Healthcare.
You may also be interested in...
The radiotherapeutics sector is attracting a new and diverse group of biopharma players hoping to capitalize on the potential advantages offered by newer therapeutic radioisotopes.
Erbitux wins FDA approval for first-line metastatic colorectal cancer negative for KRAS mutations detected with a companion diagnostic specifically approved for the drug. In theory, earlier use could help shore up sales. But the drug faces a tough competitor in the dominant Avastin and new products are on the near horizon.
Reckitt Benckiser reorganizes to emphasize consumer healthcare and emerging markets, both high growth areas for the firm. The firm’s fiscal 2011 total net revenues were $15 billion, driven by emerging markets and brands including Mucinex decongestants, Nurofen analgesics and Strepsils sore throat treatments.